Focal's sealant to get expedited FDA review:
This article was originally published in Clinica
The premarket approval application for US firm Focal's FocalSeal-L surgical sealant has been accepted by the FDA under its expedited review procedures. FocalSeal is a synthetic absorbable liquid for sealing air leaks from the lungs during thoracic surgery. The sealant is sold in Europe under licence by Johnson & Johnson subsidiary Ethicon as AdvaSeal.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.